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Abstract 
Bisphosphonates (BPs) have been shown to significantly reduce bone toughness in vertebrae 
within one year when given at clinical doses to dogs.  Although BPs also reduce toughness in 
cortical bone when given at high doses, their effect on cortical bone material properties when 
given at clinical doses is less clear.  In part, this may be due to the use of small sample sizes 
that were powered to demonstrate differences in bone mineral density rather than bone’s 
material properties. Our lab has conducted several studies in which dogs were treated with 
alendronate at a clinically relevant dose.  The goal of this study was to examine these published 
and unpublished data collectively to determine whether there is a significant time-dependent 
effect of alendronate on toughness of cortical bone. This analysis seemed particularly relevant 
given the recent occurrence of atypical femoral fractures in humans.  Differences in the 
toughness of ribs taken from dogs derived from five separate experiments were measured.  The 
dogs were orally administered saline (CON, 1 ml/kg/day) or alendronate (ALN) at a clinical dose 
(0.2 mg/kg/day).  Treatment duration ranged from 3 months to 3 years. Groups were compared 
using ANOVA, and time trends analyzed with linear regression analysis. Linear regressions of 
the percent difference in toughness between CON and ALN at each time point revealed a 
significant reduction in toughness with longer exposure to ALN. The downward trend was 
primarily driven by a downward trend in post-yield toughness, whereas toughness in the pre-
yield region was not changed relative to CON.  These data suggest that a longer duration of 
treatment with clinical doses of ALN results in deterioration of cortical bone toughness in a time-
dependent manner.  As the duration of treatment is lengthened, the cortical bone exhibits 
increasingly brittle behavior. This may be important in assessing the role that long-term BP 
treatments play in the risk of atypical fractures of femoral cortical bone in humans. 
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Introduction  
Alendronate (ALN), a bisphosphonate (BP), improves bone strength by reducing bone turnover 
(~70%) and increasing bone density, but evidence from animal studies [see [1] for review] and 
human case control studies [see [2,3] for review] suggests that this may come at the expense of 
impaired material properties. It is well established that 1-3 years treatment with oral ALN [4] or 
other BPs [5] is associated with a reduction in cancellous bone toughness, a material measure 
of energy to failure, even at clinical doses [6-8].  Similar reductions in tissue toughness can be 
inferred from recent data in ovariectomized nonhuman primates [9].  In that study, energy 
absorption in the lumbar vertebrae of ALN treated primates was similar to that in OVX animals, 
but BV/TV was higher [Mashiba, pers. comm.], implying reduced toughness. 
The data regarding impaired mechanical properties in cortical bone is less convincing, but in 
light of recent evidence of atypical femoral fractures in cortical bone especially after prolonged 
treatment with BPs, such data are of extreme importance.  The first study to show in an animal 
model that one year of treatment with ALN had negative effects on cortical bone toughness of 
the rib [4] used doses of ALN that were five times higher than those given clinically.  A later 
study [10] confirmed that finding following three years of high dose ALN.  Three-point bending of 
cortical beams from the tibia of dogs treated for one year with a high dose of ALN or risedronate 
(RIS) also resulted in significantly lower post-yield toughness [11].  High dose treatment with 
zoledronate (ZOL) reduced rib toughness after 9 months [12]. On the other hand, neither RIS 
[13] nor incadronate [14] were associated with a significant reduction in rib toughness following 
1-3 years of treatment at 2.5-5x the clinical doses.  The data seem clear that high dose ALN 
administration is associated with reductions in cortical bone toughness following 1-3 years of 
treatment, although other BPs may not be implicated.   
At clinical doses, although ALN resulted in a 19% decrease in rib cortical bone toughness after 
three years of treatment in dogs, this was not statistically different than placebo-treated animals 
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[10].  Measurements of femoral diaphyseal toughness in the canine model did not demonstrate 
a significant decline at either clinical or higher doses of ALN after three years of treatment [15]. 
However, cyclic fatigue loading of ribs from dogs treated for three years with ALN at the high 
dose resulted in a statistically significant 3-fold reduction in fatigue life compared to placebo-
treated controls, suggesting reduced toughness.  In this cyclic loading study, there was a 
significant trend for a dose effect detected by ANCOVA, but no significant difference was 
detected between the clinical dose of ALN and controls on a pairwise comparison [16].  
Given that long-term treatment with BPs, on the order of five years or more, has been 
associated with serious side effects such as atypical femoral fractures [2,3], which occur in 
cortical bone, it is important to determine whether the intrinsic material properties of cortical 
bone, in particular toughness, are significantly impaired by BP treatment at clinical doses.  The 
failure to demonstrate statistical significance using clinical doses of ALN even with relatively 
large declines in toughness of cortical bone in some studies suggests that the sample sizes 
used in most large animal studies are not adequately powered to clearly identify effects on 
toughness. The goal of this work was to examine collectively cortical bone data from several of 
our previous studies, including new unpublished data from recent mechanical tests of dogs that 
were treated with ALN at clinical doses for 3, 6, 12 or 24 months.  We hypothesized that there 
would be a significant reduction in toughness that was time-dependent.  
Methods 
All studies described herein utilized skeletally mature female beagles that began treatment 
around 1 year of age.  Animals were part of 5 separate experiments that differed only by 
duration with the treatment phase lasting 3 months, 6 months, 1 year, 2 years, or 3 years.  
While data from several of these experiments have been previously published [6,8,10,17], rib 
toughness data have only been reported for the 3 year animals [10].  The Indiana University 
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School of Medicine Animal Care and Use Committee approved all experiments prior to initiation 
of each study. 
 
In each experiment, animals were treated with either saline as a control (CON, 1 ml/kg body 
weight) or alendronate (ALN, 0.2 mg/kg body weight) via a daily oral dosing regimen.  The ALN 
dose was chosen to approximate the clinical therapeutic dose for osteoporosis on a mg/kg 
basis.  At the conclusion of the treatment duration animals were euthanized with sodium 
pentobarbital.  Ribs were excised, wrapped in saline soaked gauze, and stored at -20C until 
use. 
 
Prior to mechanical testing, ribs were thawed to room temperature, cut to ~40 mm in length with 
the mid-point falling near the point of greatest curvature.  The mid-point was marked and bone 
diameter in the AP direction at this site measured using digital calipers.  Bones from 3 month, 6 
month, and 3 year experiments were subjected to pQCT prior to mechanical testing.  A single 
slice was taken at the point of testing using a Stratec Research M scanner at the maximal 
resolution (70 microns).  Ribs from animals treated for 1 or 2 years were imaged with microCT 
after completion of mechanical testing.  A region of interest centered at the point of failure was 
scanned using a Skyscan 1172 system at a resolution of 12 microns.  A single slice, centered 
within this region of interest was reconstructed and analyzed.  For both pQCT and microCT, the 
average cross-sectional moment of inertia (CSMI) of each individual dog was used to normalize 
mechanical test data to derive material properties. 
 
All ribs were subjected to 3-point bending to determine their mechanical properties.  Bones were 
thawed to room temperature and hydration was assured by soaking in PBS prior to testing.  
Mechanical tests were conducted on a servo-hydraulic test system (Test Resources for the 3 
month, 6 month, 1 year, and 2 year experiments; MTS System for the 3 year experiment).  For 
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all tests, bones were placed on the support set up with the convex surface of the rib facing 
upward on a 25 mm bottom support span.  Tests were conducted at a displacement rate of 20 
mm/min with data collection of load vs displacement at 20Hz.  Whole bone mechanical 
properties were determined by analysis of the load-displacement curve.  Toughness (u) was 
estimated by normalizing energy absorption to fracture (as well as pre- and post-yield) using the 
standard equation of u = 0.75 * energy absorption * (diameter2 / (span length * CSMI). The yield 
point was determined using the 2% offset criterion. 
Statistical tests were performed on toughness data using ANOVA followed by pairwise 
comparisons at each time point. Linear regressions of percent difference between CON and 
ALN were run to assess time trends using intercept and slope values.  For all tests, a two-sided 
p value of < 0.05 was considered as statistically significant. 
Results 
Toughness, a measure of the intrinsic ability of the material to resist fracture, was lower in 
animals treated with ALN for at least a year, with borderline significance at the 3-year time point 
(-19%; p=0.06) (Figure 1A). Separation of toughness into pre-yield and post-yield components 
revealed similar results for post-yield toughness (3 year difference of 19%; p=0.06) with no 
differences in pre-yield toughness (Figure 1B and 1C).   
Due to variability in CON animals across time points, possibly due to age-related effects, the 
influence of ALN was evaluated by determining percent difference between CON and ALN 
within time point.  Linear regressions revealed a significant downward slope in toughness over 
time (y = -8.43x + 6.98; p = 0.042, Figure 2). The intercept was not significantly different than 0 
(p = 0.23).  The downward trend was similarly evident, although not statistically significant for 
post-yield toughness (slope p value = 0.13; intercept p value = 0.60) while there was no 
observed trend for pre-yield toughness over time (slope p value = 0.88; intercept p value = 
0.84).   
7	  
	  
Discussion 
These new data and analyses suggest that longer duration ALN treatment, at doses equivalent 
on a mg/kg basis to those used in the treatment of post-menopausal osteoporosis, will result in 
deterioration of cortical bone toughness in a time-dependent manner. Prior to one year of 
treatment there is a trend toward improved toughness, probably as a function of reduced 
remodeling that increases bone mineral density by up to 14% [4].  However, by one year of 
treatment, toughness is non-significantly lower than control and this difference remains through 
3 years of treatment. There is a significant trend toward reduction in the energy absorbing 
capacity of cortical bone tissue between 1 and 3 years of treatment. In association with a 
suppression of remodeling that suppresses the repair of microdamage [4,10], this could lead to 
a downward spiral resulting in a bone fracture that has the appearance of a stress fracture.  
Moreover, extrapolated out to 5-7 years of treatment, the average duration of treatment for 
those patients on ALN who present with an atypical femoral fracture (AFF), these data suggest 
that long-term continuous treatment could be associated with a reduction in toughness well 
beyond 20% relative to an untreated control population.  Although it is impossible to determine 
whether the monotonic decline in toughness would continue as it does in the first three years, 
this trend with clinical dosing regimens should nevertheless be a cause for concern. 
The reduced bone toughness appears to occur almost exclusively in the post-yield portion of the 
stress-strain curve.  Pre-yield toughness is largely determined by the elastic properties of the 
bone – its strength and stiffness – which are known to be improved with alendronate treatment.  
In this region, when the load on the bone is released, there is no permanent damage and the 
bone recovers its original properties (with some loss of energy).  Toughness measured after the 
yield point - post-yield toughness - is a measure of the bone’s capacity to absorb energy after 
permanent damage has occurred from microcrack formation.  Once this point has been 
reached, the bone is not able to recover its original properties without a period of time for 
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remodeling and repair.  A smaller period of post-yield deformation results in lower toughness 
and can be a sign of increasing brittleness of the bone tissue.   
Reduced post-yield toughness is consistent with previous data that indicates that cortical bone 
ultimate stress and modulus, pre-yield measurements of bone’s intrinsic mechanical properties, 
are not affected significantly by ALN treatment [4,10,14].  The localization of reduced toughness 
to the post-yield portion of the stress-strain curve clearly implicates increased tissue brittleness 
as a cause of the impaired properties.  This observation may be important given the 
fractography of atypical femoral fractures (AFF).  These fractures are unusual in that they are 
not oblique, as femoral osteoporotic fractures typically are, but rather progress transversely 
across the femoral cortex, more typical of a brittle-type fracture.  
Although the risk for and incidence of AFFs increases markedly with longer duration 
bisphosphonate treatment [18,19]  the results of our current analysis showing a significant 
decline in toughness over time begs the question about why the clinical situation is not worse for 
patients who have been on alendronate for a long period of time.   One answer to this may be 
that the increased BMD and preserved architecture associated with alendronate treatment 
compensates, in some individuals or for some period of time, at the structural level for the 
negative effects of alendronate on material properties.  It is also possible that suppression of the 
normally high rate of bone turnover in the rib accelerates the process of material degradation, 
although even greater reductions in toughness were found in the vertebral trabecular bone in 
the same animals despite slower remodeling rates [8]. 
It is not possible to determine whether similar effects on tissue properties would be caused by 
treatment at clinical doses using other BPs.  Pre-clinical data on dogs using risedronate at 
clinical doses [4,6,13] have only used experimental treatment periods up to one year.  Pre-
clinical data using incadronate in dogs did not use a clinically-relevant dose [14].  Pre-clinical 
studies using other large animal models typically have not measured changes in cortical bone 
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toughness [9,20] and so would not have been able to detect this negative trend on bone’s 
energy absorption capacity. Our own studies on dog femoral beams did not show an effect of 
ALN treatment on toughness [15]. 
It is difficult to identify long-term problems that may occur with any pharmaceutical treatment, in 
part because it is too expensive to perform long-term studies with large animals.  The use of 
large animals is particularly important for cortical bone assessment, as rodents do not typically 
undergo intracortical remodeling.  As a key effect of bisphosphonates is to reduce remodeling, 
the cortical bone response to bisphosphonates will be fundamentally different in rodents and 
larger species.   Because of the high cost and strict federal regulation of large animals, these 
studies are often conducted with the smallest sample size within each time cohort that can 
provide adequate statistical power.  Statistical power, as in this case, is often calculated based 
on outcome measures that are expected to change with treatment (eg BMD).  However, when 
an important variable, such as toughness, unexpectedly changes as in our studies, any single 
study may not be sufficiently powered to unequivocally demonstrate the significance of the 
change in that parameter.  In these cases, analyzing data from several studies collectively, as 
we have done here, can be a powerful means to demonstrate consistent and significant 
changes with duration of treatment.  
One limitation of this work is that the dogs were not ovariectomized, and thus do not represent 
an estrogen-deficient state as would be present in patients treated with bisphosphonates for 
post-menopausal osteoporosis.  With low levels of circulating estrogen, most studies have 
shown that ovariectomy has minimal effect on the dog skeleton with respect to increasing 
remodeling rate and decreasing bone mass [21,22].  It is also important to note that since the 
data presented here is a compilation of experiments conducted over nearly 10 years, some of 
the methods (specifically imaging to determine cortical bone geometry) were different among 
studies. The methods were internally consistent within time point (control and treated animals 
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were assessed similarly) making the comparisons valid.  Finally, it would have been desirable to 
use more sophisticated statistical methodology. However, the statistical approach was limited 
because (a) each animal is represented by only a single data point so we cannot account for 
baseline values or within subject variations; (b) there are too few time points to allow for more 
complex models that could evaluate trends; and (c) the animals were rather homogeneous in 
terms of sex (female), species (beagle), and age (1- 4 years old).  This prevents the evaluation 
of covariate effects. Therefore, a linear model including ANOVA is the appropriate approach. 
 
In conclusion, these new data suggest that alendronate treatment at clinical doses is associated 
with a significant time-dependent decline in cortical bone energy absorption capacity.  Changes 
occur in the post-yield region of the loading curve, suggesting that long duration bisphosphonate 
treatment is associated with brittle behavior of the cortical bone.  Given the recent increase in 
incidence of atypical femoral fractures, and the future projected increase with longer-term 
treatments [18] , this should be a significant cause for concern. 
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Figure Legends 
 
Figure 1.  Toughness of rib cortical bone following 3 months to 3 years of treatment with oral 
alendronate (0.2 mg/kg/day orally) compared to control animals. (A) Toughness, (B) Pre-yield 
toughness, and (C) post-yield toughness.  Data presented as mean and standard deviations. 
 
Figure 2.  Linear regression of alendronate’s effect over time relative to control animals showed 
a significant duration-dependent decline in toughness (p = 0.042).  Data presented as mean and 
standard deviations. 
 
	  




